Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C

Abstract

OBJECTIVE To explore the expected long-term health and economic outcomes of telaprevir (TVR) plus peginterferon alfa-2a and ribavirin (PR), a regimen that demonstrated substantially increased sustained virologic response (SVR) compared with PR alone in adults with chronic genotype 1 hepatitis C virus (HCV) and compensated liver disease in the Phase III… (More)
DOI: 10.1371/journal.pone.0090295

5 Figures and Tables

Topics

  • Presentations referencing similar topics